Effects and Mechanisms of Five Psoralea Prenylflavonoids on Aging-Related Diseases
Summary of anti-inflammation experiments of five psoralea prenylflavonoids.
Cells or animals
2, 5, 10 μmol/L
(i) Concentration-dependent inhibitory effects on NO and PGE2 production with an IC50 for inhibiting NO production: (ii) Blocked the I-κBα degradation and downregulated NF-κB activity (iii) Inhibited the iNOS and COX-2 mRNA and protein expression
(i) Upregulated aggrecan and collagen type II expression in a dose-dependent manner (ii) Inhibited MMP-1/3/13, and ADMATS-4/5 expression, and upregulated TIMP-1/2/3/4 expression (iii) Inhibited iNOS and COX-2 expression and downregulated NO and PGE2 in a dose-dependent manner
Murine J774A.1 cells and murine peritoneal macrophages
10, 20, 30, 40 μmol/L
(i) Inhibited iNOS and mPGES-1 expression and downregulated NO and PGE2 in a dose-dependent manner (ii) Inhibited phosphorylation of JNK 1/2 and ERK 1/2, and downregulated NF-κB activity (iii) Suppressed production of IL-β and the expression of NLRP3 inflammasome complex (iv) Inhibited production of NO, IL-6 and IL-12p40 in LPS-stimulated murine peritoneal macrophages
5, 10, 20 mg/kg, oral gavage after animal modeling, daily
(i) Improved the area of cerebral infarction, brain edema, and neurobehavioral indexes 48 hours after MCAO/R (ii) Lowered active-PARP and cleaved-caspase-3 levels (iii) Inhibited IL-1β, TNF-α, and IL-6 production in ischemic cerebral homogenate (iv) Reduced NLRP3/GSDMD-mediated pyroptosis of brain tissue and cells
We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.